新型冠状病毒肺炎事件下市级药物警戒工作实践与思考

doi:10.19803/j.1672-8629.2020.10.08

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (10): 688-691.
DOI: 10.19803/j.1672-8629.2020.10.08

新型冠状病毒肺炎事件下市级药物警戒工作实践与思考

吴文宇, 肖霄, 吴建茹

深圳市药物警戒和风险管理研究院,广东深圳 518024

收稿日期:2020-10-14 修回日期:2020-10-14 出版日期:2020-10-15 发布日期:2020-10-13
作者简介:吴文宇,男,本科,主管药师,药物警戒与风险管理。
基金资助:
广东省药品不良反应监测中心委托项目：粤港澳大湾区药物警戒模式研究

The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19

WU Wenyu, XIAO Xiao, WU Jianru

Shenzhen Institute of Pharmacovigilance and Risk Management, Shenzhen Guangdong 518024, China

Received:2020-10-14 Revised:2020-10-14 Online:2020-10-15 Published:2020-10-13

摘要/Abstract

摘要： 目的以深圳市为例对新型冠状病毒肺炎疫情期间市级药物警戒实践及制度建设进行思考。方法对深圳市在疫情防控期间的药物警戒工作实践进行总结,并通过文献研究方法对药物警戒理论内涵、体系构成等进行分析。结果突发公共卫生事件下的药物警戒工作开展需建立更加完善的风险监测、数据共享和利用机制。结论应从国家层面将药物警戒制度建设纳入突发公共卫生技术体系建设总体规划,从拓展数据来源、加强信息化建设、构建数据共享机制、制定有效应急处置预案等方面,提高药品风险监测应急处置能力和药品监管的科学性。

关键词: 新型冠状病毒肺炎, 突发公共卫生事件, 药物警戒, 工作实践

Abstract: Objective To summarize the practice of pharmacovigilance in Shenzhen during the outbreak of COVID-19, and to consider the construction of pharmacovigilance system. Methods On the basis of pharmacovigilance practice in Shenzhen, literature research was conducted to analyze the theoretical connotation and system composition of pharmacovigilance. Results The development of pharmacovigilance work under public health emergencies required the establishment of a more complete risk monitoring, data sharing, and utilization mechanism. Conclusion It is necessary to incorporate the construction of the pharmacovigilance system into the overall public health technology system plan from a national perspective, and to improve the capacity of drug risk monitoring and emergency response in terms of expanding data sources, strengthening information construction, building a data sharing mechanism, and formulating effective emergency response plans.

Key words: COVID-1P, emergencies in public health, pharmacovigilance, practices

中图分类号:

R951

吴文宇, 肖霄, 吴建茹. 新型冠状病毒肺炎事件下市级药物警戒工作实践与思考[J]. 中国药物警戒, 2020, 17(10): 688-691.

WU Wenyu, XIAO Xiao, WU Jianru. The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19[J]. Chinese Journal of Pharmacovigilance, 2020, 17(10): 688-691.

参考文献

[1] Wang LH.Characteristics and countermeasures of 2019-nCoV infection[J]. Chinese Journal of Experimental and Clinial Infectious Diseases(中华实验和临床感染病杂志(电子版)), 2020, 14(1): 1-5.
[2] Bian Y, Yang ZY, Xiong Y, et al.Discussion on clinical pharmaceutical service model in prevention and treatment of corona virus disease 2019[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2020, 39(4): 212-217.
[3] Song Y, Yang Y.Establishment and Operation of EU Pharmacovigilance System and Its Implementation Progress[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(7): 401-406.
[4] Song L, Zhang BK.Pharmacovigilance Systems in Europe and US and Its Impl ication for China[J]. China Pharmacy(中国药房), 2009, 20(14):1043-1045.
[5] Bihan K, Lebrun-Vignes B, Funck-Brentano C, et al.Uses of pharmacovigilance databases: An overview[EB/OL].(2020-02-26) [2020-04-23].https://doi.org/10.1016/j.therap.2020.02.022.
[6] Begaud B.Pharmacovigilance in France: a decentralized approach// Strom BL, Velo G. Drug epidemiology and post-marketing surv- eillance[M]. New York: Pleunm Press, 1992.
[7] Cai W, Ji DX, Zhao X.The Distinction of Pharmacovigilance with Adverse Drug Reaction Monitoring[J]. International Medicine and Health Guidance News(国际医药卫生导报), 2006, 12(20):48-50.
[8] Su C, Qiu JX.Introduction and inspiration of pharmacovigilance additional monitoring in European Union[J]. Drug Evaluation Research(药物评价研究), 2014, 37(1):7-10.
[9] Wu T, Chu WG, Liu ZY.The study on the construction and operation of strategic national stockpile of USA[J]. Chinese Pharmaceutical Affairs(中国药事), 2009, 23(12):1230-1233.
[10] Du WM, Zhang JH, Wang LX.The importance of pharmacovigilance- drug safety monitoring (2)[J]. Drug Evaluation(药品评价), 2004, 1(2):106-114.
[11] Liu W, Chen YX.Adverse Drug Reaction Monitoring and Pharmacovigilance[J]. China Licensed Pharmacist(中国执业药师), 2008, 5(8):18-20.
[12] Hu JL, Xu ZM, Luo ZY. Construction of emergency medicine guarantee system for public health emergencies[J]. Hospital Adm- inistration Journal of Chinese People's Liberation Army(解放军医院管理杂志), 2013, 20(8):722, 742.
[13] Li YR, Cui YM, Wang HX, et al.Enlightenment of American medical countermeasures policies on the drug evaluation, approval and management in response to public health emergencies in China[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(7):907-911.
[14] Sun Y.Considerations on drug review and approval policies related to public health emergencies[J]. Drug Evaluation Research(药物评价研究), 2020, 43(3):402-411.
[15] Xu DQ, Xu XJ, Wang J.Practice and Thinking of Drug Emergency Support for Sudden Public Health Events[J]. Chinese Journal of Medical Guide(中国医药导刊), 2009, 11(12):2166-2167.
[16] Wang CG, Wang DF, Xu LL, et al.Investigation and reflection onf the demand of public reporting of adverse drug reaction in China[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(7): 402-406.
[17] Hou YF, Wang L, Dong D, et al.Research of Data Mining in Monitoring Risk of Vaccines[J]. Chinese Pharmaceutical Affairs(中国药事), 2011, 25(5):434-437.
[18] Berbain T, Pariente A, Miremont-Salamé G, et al.Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database[J]. Drug Safety, 2020, 43(3): 243-253.
[19] Wang L.Opportunities and Challenges in Using Medical Big Data to Monitor and Evaluate Drug Safety[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2015, 12(11):660-664.
[20] Xu YM, Li XL, Wang L, et al.Exploration of the connection between hospital information system and national adverse drug reaction monitoring system[J]. Chinese Journal of Medical Guide(中国医药导刊), 2017, 19(3):317-318.
[21] Tan ZX, Wu ST, Han XP.References and enlightenments from the public health emergency response systems of the United States of America and Japan-Pneumonia epidemic response to novel coronavirus pneumonia in China[J]. Health Economics Research(卫生经济研究), 2020, 37(3) :11-16.
[22] Tang R, Liu ZX.Emergent medicine supply in momentous public emergency events[J]. Herald of Medicine(医药导报), 2009, 28(4): 407-410.
[23] Jiang T, Liao YB, He SZ, et al.Analysis of literacy on safe drug use and its influencing factors among residents of Yuexiu district, Guangzhou[J]. Chinese Journal of Health Education(中国健康教育), 2013, 29(10):923-926.
[24] Wang T, Wang D, Dong D.Thoughts on Constructing Chinese Pharmacovigilance System[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2019(1):37-41.

新型冠状病毒肺炎事件下市级药物警戒工作实践与思考

The Practice and Thinking of Pharmacovigilance at the Municipal Level under COVID-19

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[2]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[3]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[4]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[5]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[6]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[7]	张雨琪, 徐昕怡, 朱兰, 朱彦. 药品剂型标准术语的比较研究[J]. 中国药物警戒, 2023, 20(8): 904-910.
[8]	郑轶, 罗枭, 张朋朋, 刘永梅, 叶小飞, 郭晓晶, 陈霞, 贺佳. 基于主动监测系统的免疫检查点抑制剂心肌炎不良反应探索[J]. 中国药物警戒, 2023, 20(6): 634-638.
[9]	梁士兵, 余泽宇, 孔令垚, 晏利姣, 韩梅, 吴嘉瑞, 刘兆兰, 刘建平. 文献计量法在中药药物警戒领域中的应用价值及展望[J]. 中国药物警戒, 2023, 20(5): 591-594.
[10]	霍佩琼, 郑鹏, 苏振浩. 特殊或重大疾病零售药店开展药物警戒活动的思考[J]. 中国药物警戒, 2023, 20(4): 428-432.
[11]	叶培, 张鹤巍, 吕强, 叶小飞, 许金芳, 郭晓晶. 基于FAERS 数据库舒更葡糖逆转神经肌肉阻滞安全性研究[J]. 中国药物警戒, 2023, 20(3): 321-325.
[12]	逄瑜, 刘博, 吴文宇, 田月洁, 王涛. 英国患者报告制度建立的浅析与启示[J]. 中国药物警戒, 2023, 20(11): 1259-1263.
[13]	贾晋生, 王青, 刘红亮, 侯永芳. 药品上市许可持有人药物警戒工作评估指标体系的探索[J]. 中国药物警戒, 2023, 20(10): 1090-1094.
[14]	王涛, 郑明节, 刘红亮, 王青, 沈传勇. 人工智能在美国药物警戒中的应用现状及启示[J]. 中国药物警戒, 2023, 20(10): 1129-1133.
[15]	郑轶, 翟映红, 郭晓晶, 许金芳, 迟立杰, 郭志坚, 陈晨鑫, 梁际洲, 韦连慧, 陈枭, 叶小飞, 贺佳. 免疫检查点抑制剂甲状腺免疫相关不良反应分析[J]. 中国药物警戒, 2023, 20(1): 92-95.